Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

ABSTRACT: Accurate assessment of neuroblastoma outcome prediction remains challenging. Therefore, this study aims at establishing novel prognostic tumor DNA methylation biomarkers. In total, 396 low- and high-risk primary tumors were analyzed, of which 87 were profiled using methyl-CpG-binding domain (MBD) sequencing for differential methylation analysis between prognostic patient groups. Subsequently, methylation-specific PCR (MSP) assays were developed for 78 top-ranking differentially methylated regions and tested on two independent cohorts of 132 and 177 samples, respectively. Further, a new statistical framework was used to identify a robust set of MSP assays of which the methylation score (i.e. the percentage of methylated assays) allows accurate outcome prediction. Survival analyses were perf

SUBMITTER: Decock A 

PROVIDER: S-EPMC4811509 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature